# Symbicort Aerosphere (budesonide; formoterol fumarate) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/budesonide-formoterol

> The FDA approved Symbicort Aerosphere (budesonide; formoterol fumarate), sponsored by ASTRAZENECA PLC (AZN), on April 28, 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Symbicort Aerosphere (budesonide; formoterol fumarate) |
| Codes |  |
| Sponsor | ASTRAZENECA PLC (AZN) https://sec-api.dev/companies/azn/catalysts |
| Indications | [Severe Asthma](https://sec-api.dev/indications/severe-asthma) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### April 28, 2023: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA216579 ORIG-1 (Efficacy): submission_status AP, submission_status_date 20230428, review_priority STANDARD; sponsor_name ASTRAZENECA; product SYMBICORT AEROSPHERE (BUDESONIDE; FORMOTEROL FUMARATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216579%22

### April 27, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA216579 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20260427, review_priority STANDARD; sponsor_name ASTRAZENECA; product SYMBICORT AEROSPHERE (BUDESONIDE; FORMOTEROL FUMARATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216579%22

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Severe Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06473779 (Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-25 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06473779

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Severe Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06473779 (Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-25 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06473779

## Same indication

- [GB-0895](https://sec-api.dev/pdufa/gb-0895) (GENB)
- [TEZSPIRE® (tezepelumab)](https://sec-api.dev/pdufa/tezepelumab) (AZN)
- [Verekitug (upb-101)](https://sec-api.dev/pdufa/verekitug-upb-101) (UPB)

Calendar months: [June 2027](https://sec-api.dev/fda-calendar/2027-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/budesonide-formoterol.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Symbicort Aerosphere (budesonide; formoterol fumarate) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/budesonide-formoterol

```bibtex
@misc{secapidev_pdufa_budesonide_formoterol_20261116,
  title        = {Symbicort Aerosphere (budesonide; formoterol fumarate) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/budesonide-formoterol}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_budesonide_formoterol_20261116","title":"Symbicort Aerosphere (budesonide; formoterol fumarate) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/budesonide-formoterol","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
